Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.

This study has been completed.
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00654875
First received: April 3, 2008
Last updated: June 24, 2011
Last verified: June 2011

April 3, 2008
June 24, 2011
March 2008
November 2008   (final data collection date for primary outcome measure)
Change From Baseline to Week 6 in the Mean 24-hour Ambulatory Diastolic Blood Pressure (MADBP) [ Time Frame: Baseline, Week 6 ] [ Designated as safety issue: No ]
An Ambulatory Blood Pressure Monitoring (ABPM) device was attached to the non-dominant arm of the participant. The mean of Blood Pressure readings during the 24 hour period were calculated. The difference of the 24 hour MADBP from baseline to the 24 hour MADBP at 6 weeks was calculated using an Analysis of covariance (ANCOVA) model with baseline mean 24 hour ambulatory diastolic blood pressure as a covariate.
Compare the efficacy of aliskiren 300 mg once per day to aliskiren 150 mg twice a day in reducing 24-hour mean ambulatory diastolic blood pressure (MADBP) from baseline to end of Period 2 (week 6) [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00654875 on ClinicalTrials.gov Archive Site
  • Change From Baseline to Week 6 in the Mean Ambulatory Diastolic Blood Pressure (MADBP) During the Last 3 Hours of the 24-hour Dosing Period [ Time Frame: Baseline, Week 6 ] [ Designated as safety issue: No ]
    An Ambulatory Blood Pressure Monitoring (ABPM) device was attached to the non-dominant arm of the participant. The mean of Blood Pressure readings during the 22-24 hour period were calculated. The difference from the last 3 hours MADBP at baseline to the last 3 hour MADBP at Week 6 was calculated using an ANCOVA model with baseline mean 24 hour ambulatory diastolic blood pressure as a covariate.
  • Change From Baseline to Week 6 in the Mean Ambulatory Systolic Blood Pressure (MASBP) During the Last Three Hours of the 24-hour Dosing Period [ Time Frame: Baseline, Week 6 ] [ Designated as safety issue: No ]
    An Ambulatory Blood Pressure Monitoring (ABPM) device was attached to the non-dominant arm of the participant. The mean of Blood Pressure readings during the 22-24 hour period were calculated. The difference from the last 3 hours MASBP at baseline to the last 3 hour MASBP at Week 6 was calculated using an ANCOVA model with baseline mean 24 hour ambulatory systolic blood pressure as a covariate.
  • Change From Baseline to Week 6 in the Mean 24-hour Ambulatory Systolic Blood Pressure (MASBP) [ Time Frame: Baseline, Week 6 ] [ Designated as safety issue: No ]
    An Ambulatory Blood Pressure Monitoring (ABPM) device was attached to the non-dominant arm of the participant. The mean of Blood Pressure readings during the 24 hour period were calculated. The difference of the 24 hour MASBP from baseline to the 24 hour MASBP at 6 weeks was calculated using an ANCOVA model with baseline mean 24 hour ambulatory systolic blood pressure as a covariate.
  • Change From Baseline to Week 6 in the Mean Sitting Systolic and Mean Sitting Diastolic Blood Pressure [ Time Frame: Baseline, Week 6 ] [ Designated as safety issue: No ]
    After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A negative number indicates lowered blood pressure. The ANCOVA model used baseline as a covariate.
  • Percentage of Participants Achieving Blood Pressure Control at Week 6 [ Time Frame: Week 6 ] [ Designated as safety issue: No ]

    After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer. The mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure at visit 3 (week 6).

    Blood pressure control was defined as having a mean sitting diastolic blood pressure (msDBP) <90 mm Hg and a mean sitting systolic blood pressure (msSBP) <140 mm Hg.

  • Percentage of Participants Achieving Blood Pressure Control at the End of the Study (Week 10) [ Time Frame: Week 10 ] [ Designated as safety issue: No ]

    After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer. The mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure at visit 4 (week 10).

    Blood pressure control was defined as having a mean sitting diastolic blood pressure (msDBP) <90 mm Hg and a mean sitting systolic blood pressure (msSBP) <140 mm Hg.

  • Evaluate the efficacy of aliskiren 300 mg compared to aliskiren 150 mg (2/day)in reducing mean ambulatory diastolic blood pressure and mean ambulatory systolic blood pressure during the last three hours of the 24-hour dosing period - from baseline to the [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • • Evaluate the efficacy of aliskiren 300 mg once per day compared to aliskiren 150 mg twice per day in reducing 24-hour mean ambulatory systolic blood pressure (MASBP) from baseline to the end of period 2 (week 6). [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • • Evaluate the proportion of patients achieving blood pressure control target (140/90 mm Hg) in each treatment arm from baseline to end of period 2 (week 6) [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
A 10 Week, Randomized, Double-blind, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg qd) to Twice Daily Dosing of Aliskiren (150 mg Bid) in Patients With Essential Hypertension.

This study will compare the safety and efficacy of once daily dosing of aliskiren to twice daily dosing of aliskiren in patients with moderate hypertension

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Essential Hypertension
  • Drug: Aliskiren
    Aliskiren supplied in 150 mg and 300 mg tablets.
    Other Name: Tekturna, Rasilez
  • Drug: Placebo to Aliskiren
    Placebo to Aliskiren matching 150 and 300 mg tablets
  • Experimental: Aliskiren 300 mg (Once a Day)
    Participants received Aliskiren 300 mg tablet + Placebo to Aliskiren matching 150 mg tablet daily in the morning and Placebo to Aliskiren matching 150 mg tablet daily in the evening for a total of 10 weeks.
    Interventions:
    • Drug: Aliskiren
    • Drug: Placebo to Aliskiren
  • Experimental: Aliskiren 150 mg (Twice a Day)
    Participants received Aliskiren 150 mg tablet + Placebo to Aliskiren matching 300 mg tablet daily in the morning and Aliskiren 150 mg tablet daily in the evening for the first 6 weeks then for the next 4 weeks received Aliskiren 300 mg tablet + Placebo to Aliskiren matching 150 mg tablet daily in the morning and Placebo to Aliskiren matching 150 mg tablet daily in the evening.
    Interventions:
    • Drug: Aliskiren
    • Drug: Placebo to Aliskiren
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
328
November 2008
November 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Have diagnosis of uncomplicated essential hypertension; newly diagnosed or who have not received antihypertension medication within 4 weeks of visit 1 must have an office cuff mean sitting Diastolic Blood pressure (msDBP) > 100 mmHg and < 110 mmHg at visit 1. If patient is receiving antihypertensive treatment, must have a cuff msDBP > 95 mmHg and < 110 mmHg at visit 1
  • Prior to randomization, all patients must have an office cuff msDBP >or= 100 mmHg and <or = 110 mmHg.

Exclusion Criteria:

  • Participation in another aliskiren trial or previous treatment with aliskiren during last 6 months and who qualified to be randomized or enrolled into the active drug treatment period
  • Pregnant or nursing women
  • Women of child bearing potential unwilling to use protocol specific contraceptive methods
  • Office cuff blood pressure of msDBP ≥ 112 mmHg and/or mean sitting Systolic Blood Pressure (msSBP) ≥ 200 mmHg).
  • Secondary form of hypertension
  • History of heart failure New York Heart Association (NYHA Class II, III and IV)
  • Previous history of hypertensive encephalopathy or stroke, transient ischemic attack (TIA), heart attack, coronary bypass surgery or any percutaneous coronary intervention (PCI)
  • Elevated Serum potassium (> or = 5.3 mEq/L (mmol/L) at Visit 1
  • Type 1 or Type 2 diabetes mellitus not well controlled
  • Other protocol-defined inclusion/exclusion criteria may apply
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Germany,   Spain
 
NCT00654875
CSPP100A2403
No
Novartis
Novartis
Not Provided
Principal Investigator: Novartis Novartis
Novartis
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP